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Abstract Silymarin is known to have an anti-atherosclerotic
activity, but the mechanism responsible for it remains unclear.
Here, we demonstrate a possible mechanism involved in the anti-
atherosclerotic activity of silymarin. Silymarin inhibited THP-1
cell adhesion to human umbilical vein endothelial cells (HU-
VECs). Silymarin also suppressed the TNF-K-induced protein
and mRNA expression of adhesion molecules, such as VCAM-1,
ICAM-1 and E-selectin, in HUVECs. Moreover, silymarin sup-
pressed the TNF-K-induced DNA binding of NF-UB/Rel in
HUVECs. Taken together, these results demonstrate that sily-
marin exerts an anti-atherosclerotic activity, at least in part, by
inhibiting the expression of adhesion molecules.
/ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Atherosclerosis and its complications are the most common
health problem in the developed countries. Atherosclerosis
was considered as a lipid storage disease, but it is now re-
garded as a chronic in£ammatory disease and characterized
by the in¢ltration of mononuclear lymphocytes into the inti-
ma [1]. The adhesion of monocytes to the arterial wall and
their subsequent in¢ltration and di¡erentiation into macro-
phages are key events in the development of atherosclerosis
[2].
The recruitment of monocytes to the arterial wall is medi-
ated by cell adhesion molecules expressed on endothelial cells
in response to in£ammatory stimuli. The most important cell
adhesion molecule involved in this process is vascular cell
adhesion molecule-1 (VCAM-1). VCAM-1 interacts with the
monocyte integrin VLA-4 and is expressed on endothelial cells
at the sites of in£ammation [3^5]. Intercellular adhesion mol-
ecule-1 (ICAM-1) is also implicated in the adhesion of mono-
cytes to endothelial cells, and Collins and coworkers reported
that deletion of the ICAM-1 gene resulted in signi¢cant re-
ductions in monocyte recruitment to atherosclerotic lesions in
apo E-de¢cient mice [6]. It has been reported that deletion of
the gene of E-selectin, another key cell adhesion molecule in
apo E-de¢cient mice, resulted in a substantial decrease in the
severity of atherosclerosis [7].
Nuclear factor-UB/Rel (NF-UB/Rel) is known to play a crit-
ical role in the development of in£ammatory response by up-
regulating the expression of many in£ammatory mediators [8].
It has also been reported that the transcriptional activation of
NF-UB/Rel is important for the expression of proin£amma-
tory cell adhesion molecules listed above. Iademarco and co-
workers characterized two distinct NF-UB/Rel binding sites in
the upstream of VCAM-1 gene and showed that their respon-
siveness is cell-speci¢c [9]. NF-UB/Rel binding sites were also
identi¢ed in the upstream of the transcription start sites of the
ICAM-1 and E-selectin genes [10,11].
Silymarin is a £avonoid antioxidant isolated from the fruits
and seeds of the milk thistle, Silybum marianum [12]. Silyma-
rin has been clinically used to treat various liver diseases be-
cause of its hepatoprotective e¡ect [13,14]. In addition, recent
studies demonstrated an anti-in£ammatory e¡ect of silymarin
[15,16]. It has been reported that silymarin also has an anti-
atherosclerotic e¡ect [17] and its anti-atherosclerotic activity
of silymarin is mediated by the inhibition of low density lipo-
protein (LDL) oxidation and cholesterol biosynthesis [18,19].
The objective of the present study was to investigate the
e¡ect of silymarin on monocyte adhesion to endothelial cells
and the expression of cell adhesion molecules and to elucidate
the mechanism involved in the anti-atherosclerotic e¡ect of
silymarin.
2. Materials and methods
2.1. Chemicals and cell culture
All reagents were purchased from Sigma-Aldrich (St. Louis, MO,
USA) unless otherwise stated. Silymarin was dissolved in dimethyl
sulfoxide and freshly diluted in culture media for all experiments.
The human umbilical vein endothelial cells (HUVECs) were grown
in EGM-2 Bulletkit (Clonetics, BioWhittaker, Inc., MD, USA) and
the human monocyte cell line THP-1 cells (ATCC TIB202) were
grown in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin
and 100 Wg/ml streptomycin at 37‡C in 5% CO2 humidi¢ed air.
2.2. Cell adhesion assay
Assay was performed as described previously [20]. Brie£y, HUVECs
were plated in 48-well plate, grown to 70% con£uence and pretreated
with silymarin (6.25, 12.5, 25 or 50 Wg/ml) for 1 h, followed by stimu-
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lated with TNF-K (10 ng/ml) for 24 h. The cells were rinsed three
times with serum free medium, and THP-1 cells were added to each
well. After 1 h incubation, the non-adherent THP-1 cells were rinsed
o¡ and the adherent cells were collected by treatment with Trypsin-
EDTA for 1 min and counted directly under a light microscope.
Monoclonal antibodies for functional blocking of adhesion molecules
were purchased from RpD systems, Inc (Minneapolis, MN, USA).
2.3. Modi¢ed enzyme-linked immunosorbent assay (ELISA) for
measurement of the cell surface expressions of adhesion molecules
The cell surface expressions of VCAM-1, ICAM-1 and E-selectin on
HUVECs were quanti¢ed using cell-ELISA by modi¢cation of previ-
ously published methods [21]. Brie£y, HUVECs were grown to 70%
con£uence in 96-well, gelatin-coated plates and treated with silymarin
(6.25, 12.5, 25 or 50 Wg/ml) for 1 h before being treated with TNF-K
(10 ng/ml) for 24 h. Following incubation, the cells were washed with
phosphate-bu¡ered saline pH 7.4 (PBS) and ¢xed with 4% parafor-
maldehyde for 30 min at 4‡C. Non-fat dry milk (3.0% in PBS) was
added to the monolayers to reduce non-speci¢c binding. After wash-
ing three times with PBS, cells were incubated with anti-VCAM-1,
anti-ICAM-1 or anti-E-selectin monoclonal antibody overnight at
4‡C, washed with PBS and followed by incubation with peroxidase-
conjugated goat anti-mouse secondary antibody. Following this, the
cells were washed with PBS and exposed to the peroxidase substrate.
Absorbance was determined at 490 nm by an automated microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
The expressions of the mRNA transcripts of VCAM-1 (forward
primer: 5P-ATGACATGCTTGAGCCAGG-3P, reverse primer: 5P-G-
TGTCTCCTTCTTTGACACT-3P), ICAM-1 (forward primer: 5P-CA-
GTGACCATCTACAGCTTTCCGG-3P, reverse primer: 5P-GCTG-
CTACCACAGTGATGATGACAA-3P), E-selectin (forward primer:
5P-GATGTGGGCATGTGGAATGATG-3P, reverse primer: 5P-AG-
GTACACTGAAGGCTCTGG-3P) and L-actin (forward primer: 5P-
TGACGGGGTCACCCACACTGTGCCCATCTA-3P, reverse prim-
er: 5P-CTAGAAGCATTTGCGGGGACGATGGAGGG-3P) were
evaluated by RT-PCR as described previously with slight modi¢ca-
tions [22]. Brie£y, total RNA was isolated using Tri Reagent (Molec-
ular Research Center, Cincinnati, OH, USA) as described previously
[23]. Equal amounts of RNA were reverse transcribed into cDNA
using oligo(dT)15 primers. Samples were heated to 94‡C for 5 min
and cycled 25 times at 94‡C for 30 s, 60‡C for 30 s, and 72‡C for
45 s, and this was followed by an additional extension step at 72‡C for
5 min. PCR products were electrophoresed in a 1.5% agarose gel and
followed by ethidium bromide staining and photography.
2.5. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described previously [22]. The
protein content of the nuclear extracts was determined using a Bio-
Rad protein assay kit according to the manufacturer’s instructions.
The oligonucleotide sequence for NF-UB/Rel was 5P-GATCTCA-
GAGGGGACTTTCCGAGAGA-3P [24]. Double-stranded oligonu-
cleotides were end-labeled with [Q-32P]-ATP. Nuclear extracts (5 Wg)
were incubated with 2 Wg of poly(dI-dC) and a 32P-labeled DNA
probe, and DNA binding activity was analyzed using a 4.8% polyac-
rylamide gel. After electrophoresis, the gel was dried and subjected to
autoradiography. The speci¢city of binding was examined by compe-
tition with an unlabeled oligonucleotide.
2.6. Statistical analysis
The meanQS.D. was determined for each treatment group in each
experiment. Signi¢cance was determined by either Dunnett’s two-
tailed t test for comparison between two groups or by ANOVA (anal-
ysis of variance), followed by Dunnett’s test for multiple comparisons.
3. Results
3.1. Inhibitory e¡ect of silymarin on THP-1 cell adhesion to
HUVECs stimulated with TNF-K and involvement of
adhesion molecules in THP-1 cell adhesion
As described previously, monocyte adhesion to endothelial
cells is an important event in the development of atheroscle-
rotic lesion. Therefore, we examined THP-1 cell adhesion to
HUVECs stimulated with TNF-K to assess anti-atherogenic
potential of silymarin. When unstimulated, the binding of
THP-1 cells to HUVECs was lower than 20% of the TNF-
K-treated group. However, THP-1 cell adhesion was substan-
tially increased when HUVECs were stimulated with TNF-K
(10 ng/ml). Treatment of HUVECs with silymarin (6.25, 12.5,
25 or 50 Wg/ml) dramatically inhibited THP-1 cell adhesion to
TNF-K-stimulated HUVECs in a dose-dependent manner
(Fig. 1). Several cell adhesion molecules are implicated in
monocyte adhesion to endothelial cells and VCAM-1,
ICAM-1 and E-selectin have been known to play an impor-
tant role in this process (reviewed in [2]). To further con¢rm
the involvement of these adhesion molecules in the adhesion
of THP-1 cells, we examined the e¡ect of monoclonal anti-
bodies of VCAM-1, ICAM-1 and E-selectin on THP-1 cell
adhesion to TNF-K-stimulated HUVECs. Treatment of anti-
VCAM-1 antibody caused 50% inhibition of THP-1 cell ad-
hesion to HUVECs compared to TNF-K-treated group. Anti-
ICAM-1 and anti-E-selectin antibodies also blocked THP-1
cell adhesion to HUVECs (Fig. 2).
Fig. 1. E¡ect of silymarin on THP-1 cell adhesion to HUVECs
stimulated with TNF-K. HUVECs were pretreated with silymarin
(6.25, 12.5, 25 or 50 Wg/ml) for 1 h, followed by stimulated expres-
sion of adhesion molecules with TNF-K (10 ng/ml) for 24 h. The
wells, containing HUVECs, were rinsed, and THP-1 cells were
added to each well. After 1 h, non-adherent cells were rinsed o¡,
the adherent cells were collected by treatment with Trypsin-EDTA,
and counted under a light microscope.
Fig. 2. Involvement of adhesion molecules in THP-1 cell adhesion
to HUVECs. HUVECs were stimulated with TNF-K (10 ng/ml) for
24 h and treated with anti-VCAM-1, anti-ICAM-1 and anti-E-selec-
tin antibodies for 1 h. THP-1 cell adhesion was analyzed as de-
scribed in Section 2.
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3.2. E¡ect of silymarin on the cell surface expressions of
VCAM-1, ICAM-1 and E-selectin in TNF-K-stimualted
HUVECs
To further investigate the reason why the treatment of
HUVECs with silymarin inhibited THP-1 cell adhesion to
HUVECs stimulated with TNF-K, we examined the e¡ect of
silymarin on the cell surface expressions of VCAM-1, ICAM-
1 and E-selectin in TNF-K-stimulated HUVECs. As shown in
Fig. 3a, TNF-K (10 ng/ml) alone increased VCAM-1 expres-
sion by seven times the basal level in HUVECs, and this
induction of VCAM-1 expression was concentration depend-
ently suppressed by silymarin. The cell surface expressions of
ICAM-1 and E-selectin were also signi¢cantly increased by
TNF-K, but the inhibitory e¡ect of silymarin on ICAM-1
and E-selectin expression was less sensitive than that on the
VCAM-1 expression (Fig. 3b,c). The inhibitory e¡ect of sily-
marin on TNF-K-induced ICAM-1 and E-selectin expression
was smaller than that on VCAM-1 expression at low concen-
trations (6.25, 12.5 and 25 Wg/ml), but the e¡ect was signi¢-
cant at a high concentration (50 Wg/ml).
3.3. E¡ect of silymarin on the mRNA expression of VCAM-1,
ICAM-1, and E-selectin in TNF-K-stimulated HUVECs
To assess the e¡ect of silymarin on the mRNA expression
of VCAM-1, ICAM-1, and E-selectin, we measured the
mRNA levels by RT-PCR. In unstimulated HUVECs, the
mRNA expression was hardly detectable for all of VCAM-
1, ICAM-1 and E-selectin. When stimulated with TNF-K
(10 ng/ml) for 4 h, however, HUVECs expressed high levels
of VCAM-1, ICAM-1 and E-selectin mRNA. TNF-K-induced
VCAM-1 mRNA expression was suppressed by silymarin in a
dose-dependent manner (Fig. 4). Consistent with the previous
results, ICAM-1 mRNA expression was downregulated by
silymarin only at a high concentration (50 WM) in TNF-K-
stimulated HUVECs (Fig. 4). Furthermore, TNF-K-induced
E-selectin mRNA expression was also signi¢cantly inhibited
by silymarin treatment in HUVECS (Fig. 4).
3.4. Inhibition of NF-UB/Rel DNA binding by silymarin in
TNF-K-stimulated HUVECs
NF-UB/Rel is known to have a critical role in the expression
of proin£ammatory cell adhesion molecules. To examine
whether the inhibitory e¡ect of silymarin on the gene expres-
sion of VCAM-1, ICAM-1 and E-selectin was mediated by
suppressing the activation of NF-UB/Rel, the DNA binding of
NF-UB/Rel was measured in HUVECs in the presence and
absence of TNF-K and/or silymarin. Treatment of HUVECs
with TNF-K (10 ng/ml) caused a signi¢cant increase in the
Fig. 3. Inhibition of cell surface expressions of VCAM-1, ICAM-1 and E-selectin by silymarin in TNF-K-stimulated HUVECs. HUVECs were
pretreated with the indicated concentrations of silymarin for 1 h before being incubated with TNF-K (10 ng/ml) for 24 h. The cells were ¢xed
with 4% paraformaldehyde and the cell surface expressions of VCAM-1 (a), ICAM-1 (b) and E-selectin (c) were analyzed as described in Sec-
tion 2. Each column shows the meanQS.D. of triplicate determinations. *, response that is signi¢cantly di¡erent from the control group as de-
termined by Dunnett’s two-tailed t test at P6 0.05.
Fig. 4. Inhibition of the mRNA expression of VCAM-1, ICAM-1
and E-selectin by silymarin in TNF-K-stimulated HUVECs. HU-
VECs were pretreated with silymarin (6.25, 12.5, 25 or 50 Wg/ml)
for 1 h before being incubated with TNF-K (10 ng/ml) for 12 h. To-
tal RNA was isolated and the mRNA expression of VCAM-1,
ICAM-1, E-selectin and L-actin was determined by RT-PCR. One
of two representative experiments is shown.
FEBS 27539 13-8-03
J.S. Kang et al./FEBS Letters 550 (2003) 89^93 91
DNA binding activity of NF-UB/Rel within 30 min. In the
presence of silymarin, TNF-K-induced NF-UB/Rel DNA bind-
ing was markedly suppressed in a concentration-dependent
manner (Fig. 5)
4. Discussion
Silymarin is known to block the activation of the transcrip-
tion factor NF-UB/Rel stimulated by various stimuli in a va-
riety of cell types [15,16,25]. As previously described, it is also
well known that the transcription factor NF-UB/Rel is essen-
tial to the gene expression of cell adhesion molecules, such as
VCAM-1, ICAM-1 and E-selectin [9^11]. Therefore, we hy-
pothesized that silymarin has the ability to modulate the ex-
pression of cell adhesion molecules on activated endothelial
cells. To characterize this hypothesis, we examined the ability
of silymarin to inhibit the adhesion of monocytes to endothe-
lial cells and to suppress the gene expression of cell adhesion
molecules. In the present study, silymarin was found to inhibit
monocyte adhesion to endothelial cells and gene expression of
cell adhesion molecules on endothelial cells.
The recruitment of monocytes to the arterial wall and their
in¢ltration and di¡erentiation to macrophages play a protec-
tive role by removing cytotoxic and proin£ammatory oxLDL
particles or apoptotic cells. However, accumulation of macro-
phages and their uptake of oxLDL ultimately lead to the
development of atherosclerotic lesion. Moreover, oxLDL it-
self has in£ammatory and atherogenic properties and acceler-
ates the progression of atherosclerosis. Locher and coworkers
reported the inhibitory e¡ect of silymarin on LDL oxidation,
suggesting one of the possible mechanisms responsible for the
anti-atherosclerotic activity of silymarin [18]. We clearly show
here that silymarin directly inhibits the expression of cell ad-
hesion molecules, such as VCAM-1, ICAM-1 and E-selectin,
which mediate the recruitment of monocytes to the arterial
wall. NO is a potent oxidant and exerts critical and diverse
functions in the cardiovascular system and an impaired pro-
duction of NO plays a key role in the development of cardio-
vascular diseases [26]. NO is known to have both atherogenic
and vascular protective e¡ects, dependent on the source and
amount of production. NO produced by endothelial NO syn-
thase (eNOS) has a vasodilator function and has a protective
e¡ect. However, inducible NO synthase (iNOS) in macro-
phages produces a large amount of NO in response to stimuli,
and potent oxidative properties of NO produced by iNOS
appear to induce atherosclerosis. Our previous study that re-
ported the inhibitory e¡ect of silymarin on iNOS expression
in LPS-stimulated macrophages also explains the anti-athero-
sclerotic activity of silymarin [16]. Therefore, all of these
properties of silymarin seem to contribute to its anti-athero-
sclerotic activity.
Flavonoids are naturally occurring compounds and have a
wide range of biological activities. There have been numerous
reports demonstrating anti-atherosclerotic activity of £avo-
noids. Resveratrol, which is a £avonoid present in wine and
grape juice, was found to inhibit LDL oxidation [27,28]. Fer-
rero and coworkers reported that resveratrol inhibited
VCAM-1 and ICAM-1 expression [29]. A novel £avonoid,
PD098063, was also reported to have an anti-atherosclerotic
activity and have an inhibitory e¡ect on TNF-K-induced
VCAM-1 expression [30]. Quercetin, a strong anti-in£amma-
tory £avonoid, was reported to inhibit LDL oxidation and
have an anti-atherosclerotic e¡ect [31,32]. However, despite
its potent anti-atherosclerotic properties, quercetin is not ab-
sorbed into the body when orally administered [33]. On the
other hand, silymarin was reported to be distributed rapidly
to various tissues after oral administration to mice [34]. Fur-
thermore, silymarin has been clinically used for a long time to
treat various liver diseases demonstrating its good bioavail-
ability.
In conclusion, the present study demonstrates the e¡ect of
silymarin on the gene expression of proin£ammatory cell ad-
hesion molecules and indicates a new insight into the mecha-
nism responsible for the anti-in£ammatory and anti-athero-
sclerotic property of silymarin.
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